Animal Models Antiviral Research Advancing Drug Discovery

Animal models have been a cornerstone in antiviral research, offering
crucial insights into viral pathogenesis and enabling the development of
effective therapies. They facilitate the exploration of experimental
approaches that are not feasible in humans, thereby advancing our
understanding of disease mechanisms and therapeutic interventions. From
studying virus-host interactions to testing vaccines and therapeutics,
animal models are indispensable tools for antiviral drug discovery and
pandemic preparedness.

Insights from Animal Models

Animal models play a pivotal role in understanding the complexities of
viral infections and evaluating potential antiviral therapies. These
models enable researchers to explore virus-drug interactions in vivo,
which are critical for predicting the efficacy and safety of antiviral
treatments in humans (Field & Brown, 1989). For example, non-human
primates have been instrumental in HIV research, providing insights into
drug resistance, immune responses, and early treatment strategies (Van
Rompay, 2010). Similarly, studies using mice, ferrets, and guinea pigs
have advanced our understanding of influenza and the evaluation of
antiviral agents (Mifsud et al., 2018).

During the COVID-19 pandemic, animal models like ACE2 transgenic mice,
ferrets, and hamsters were key to developing vaccines and therapeutics,
including mRNA vaccines and monoclonal antibodies (Younes et al., 2020).
These efforts underscore the adaptability of animal models in responding
to emerging viral threats.

Challenges and Limitations

Despite their significance, animal models have inherent limitations. The
complexity of human viral infections means no single model can fully
replicate human disease. Differences in species-specific immune
responses often limit the translatability of findings to humans.
Additionally, the time required to develop models for emerging viruses
can delay critical research during outbreaks. Ethical considerations,
including adherence to the 3Rs (Replacement, Reduction, Refinement), are
paramount, as is the resource-intensive nature of maintaining
specialized high-containment facilities.

Innovations and Future Directions

Advancements in technology and methodology are opening new avenues in
antiviral research. The development of humanized models, incorporating
human cells or genes into animals, is enhancing the relevance of
findings to human biology. Organs-on-chips, microfluidic systems that
replicate human organ functions, offer promising alternatives to live
models, reducing reliance on animals. AI-driven analyses are providing
predictive insights into drug efficacy and toxicity, complementing
experimental findings. Furthermore, global collaborations are
accelerating the development of models and sharing data for emerging
viruses, improving our collective ability to respond to health crises.

Impactful Contributions of Animal Models

Animal models have significantly shaped antiviral research across
various diseases:

• – HIV: Non-human primates facilitated the development of

antiretroviral therapies, transforming HIV into a manageable
condition (Van Rompay, 2010).

• – Influenza: Ferrets and mice have been instrumental in annual

vaccine optimization and antiviral drug studies like oseltamivir
(Mifsud et al., 2018).

• – Ebola Virus: Studies in non-human primates were crucial for

testing vaccines such as rVSV-ZEBOV, now utilized in outbreak
responses.

• – SARS-CoV-2: Models like hamsters and mink enabled rapid vaccine

and therapeutic development during the COVID-19 pandemic (Younes et
al., 2020).

Shaping the Future of Antiviral Research

Refining animal models and integrating innovative approaches will be
vital in addressing the challenges of emerging viral threats. These
advancements promise to improve therapeutic outcomes and accelerate the
pace of discovery in antiviral research. As we navigate an ever-changing
global health landscape, the role of animal models remains indispensable
in guiding clinical studies and improving public health responses.

————————————————————————

References

 

 

• – Field, H., & Brown, G. (1989). Animal models for antiviral

 

chemotherapy. Antiviral Research, 12(4), 165–180.
<https://doi.org/10.1016/0166-3542(89)90027-2>

 

• – Mifsud, E., Tai, C., & Hurt, A. (2018). Animal models used to assess

 

influenza antivirals. Expert Opinion on Drug Discovery, 13,
1131–1139. <https://doi.org/10.1080/17460441.2018.1540586>

 

• – Van Rompay, K. (2010). Evaluation of antiretrovirals in animal

 

models of HIV infection. Antiviral Research, 85(1), 159–175.
<https://doi.org/10.1016/j.antiviral.2009.07.008>

 

• – Wahaab, A., et al. (2021). Potential Role of Flavivirus NS2B-NS3

 

Proteases in Viral Pathogenesis and Anti-flavivirus Drug Discovery.
Viruses, 14. <https://doi.org/10.3390/v14010044>

 

• – Younes, S., et al. (2020). Severe acute respiratory syndrome

 

coronavirus‐2 natural animal reservoirs and experimental models:
Systematic review. Reviews in Medical Virology, 31.
<https://doi.org/10.1002/rmv.2196>